US20050071087A1 - Systems and methods for detecting biological features - Google Patents
Systems and methods for detecting biological features Download PDFInfo
- Publication number
- US20050071087A1 US20050071087A1 US10/954,443 US95444304A US2005071087A1 US 20050071087 A1 US20050071087 A1 US 20050071087A1 US 95444304 A US95444304 A US 95444304A US 2005071087 A1 US2005071087 A1 US 2005071087A1
- Authority
- US
- United States
- Prior art keywords
- model
- test
- organism
- computer
- cellular
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims description 117
- 230000001413 cellular effect Effects 0.000 claims abstract description 410
- 239000000470 constituent Substances 0.000 claims abstract description 403
- 238000012360 testing method Methods 0.000 claims abstract description 269
- 108090000623 proteins and genes Proteins 0.000 claims description 181
- 241000894007 species Species 0.000 claims description 146
- 239000000523 sample Substances 0.000 claims description 133
- 206010028980 Neoplasm Diseases 0.000 claims description 101
- 238000004590 computer program Methods 0.000 claims description 72
- 108020004999 messenger RNA Proteins 0.000 claims description 66
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 61
- 201000010099 disease Diseases 0.000 claims description 59
- 239000002299 complementary DNA Substances 0.000 claims description 54
- 239000003814 drug Substances 0.000 claims description 51
- 229940079593 drug Drugs 0.000 claims description 50
- 201000011510 cancer Diseases 0.000 claims description 45
- 239000012472 biological sample Substances 0.000 claims description 40
- 150000007523 nucleic acids Chemical class 0.000 claims description 35
- 102000039446 nucleic acids Human genes 0.000 claims description 33
- 108020004707 nucleic acids Proteins 0.000 claims description 33
- 238000012512 characterization method Methods 0.000 claims description 29
- 208000026310 Breast neoplasm Diseases 0.000 claims description 28
- 230000007246 mechanism Effects 0.000 claims description 27
- 206010006187 Breast cancer Diseases 0.000 claims description 26
- 238000012545 processing Methods 0.000 claims description 26
- 102000004169 proteins and genes Human genes 0.000 claims description 24
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 23
- 201000005202 lung cancer Diseases 0.000 claims description 23
- 208000020816 lung neoplasm Diseases 0.000 claims description 23
- 230000035945 sensitivity Effects 0.000 claims description 20
- 230000000694 effects Effects 0.000 claims description 19
- 206010009944 Colon cancer Diseases 0.000 claims description 17
- 206010033128 Ovarian cancer Diseases 0.000 claims description 17
- 206010060862 Prostate cancer Diseases 0.000 claims description 16
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 15
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 15
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 14
- 238000003860 storage Methods 0.000 claims description 14
- 230000002103 transcriptional effect Effects 0.000 claims description 14
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 12
- 206010017758 gastric cancer Diseases 0.000 claims description 12
- 201000011549 stomach cancer Diseases 0.000 claims description 12
- 206010005003 Bladder cancer Diseases 0.000 claims description 11
- 210000002307 prostate Anatomy 0.000 claims description 11
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 10
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 10
- 206010038038 rectal cancer Diseases 0.000 claims description 10
- 201000001275 rectum cancer Diseases 0.000 claims description 10
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 10
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 9
- 210000001672 ovary Anatomy 0.000 claims description 9
- 210000000481 breast Anatomy 0.000 claims description 8
- 210000004072 lung Anatomy 0.000 claims description 8
- 238000002560 therapeutic procedure Methods 0.000 claims description 8
- 238000001574 biopsy Methods 0.000 claims description 6
- 230000001394 metastastic effect Effects 0.000 claims description 6
- 230000004481 post-translational protein modification Effects 0.000 claims description 6
- 229920002477 rna polymer Polymers 0.000 claims description 6
- 210000002784 stomach Anatomy 0.000 claims description 6
- 239000008280 blood Substances 0.000 claims description 5
- 210000004369 blood Anatomy 0.000 claims description 5
- 210000000988 bone and bone Anatomy 0.000 claims description 5
- 210000000664 rectum Anatomy 0.000 claims description 5
- 238000010846 tandem mass spectrometry analysis Methods 0.000 claims description 5
- 238000004364 calculation method Methods 0.000 description 125
- 230000014509 gene expression Effects 0.000 description 118
- 210000004027 cell Anatomy 0.000 description 102
- 238000002493 microarray Methods 0.000 description 66
- 102000040430 polynucleotide Human genes 0.000 description 60
- 108091033319 polynucleotide Proteins 0.000 description 60
- 239000002157 polynucleotide Substances 0.000 description 60
- 238000009396 hybridization Methods 0.000 description 56
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 49
- 238000004422 calculation algorithm Methods 0.000 description 45
- 238000003491 array Methods 0.000 description 35
- 108020004414 DNA Proteins 0.000 description 30
- 230000027455 binding Effects 0.000 description 30
- 108700024394 Exon Proteins 0.000 description 28
- 230000000295 complement effect Effects 0.000 description 21
- 238000005259 measurement Methods 0.000 description 20
- 230000004083 survival effect Effects 0.000 description 20
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 18
- 102100035186 DNA excision repair protein ERCC-1 Human genes 0.000 description 17
- 101000876529 Homo sapiens DNA excision repair protein ERCC-1 Proteins 0.000 description 17
- 238000004458 analytical method Methods 0.000 description 17
- 230000037361 pathway Effects 0.000 description 16
- 230000001105 regulatory effect Effects 0.000 description 16
- 238000011282 treatment Methods 0.000 description 14
- 230000004044 response Effects 0.000 description 13
- 230000000875 corresponding effect Effects 0.000 description 12
- 239000012634 fragment Substances 0.000 description 12
- 230000003211 malignant effect Effects 0.000 description 12
- 229940063683 taxotere Drugs 0.000 description 12
- 108020004635 Complementary DNA Proteins 0.000 description 11
- 230000002776 aggregation Effects 0.000 description 11
- 238000004220 aggregation Methods 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 101150071146 COX2 gene Proteins 0.000 description 10
- 101100114534 Caenorhabditis elegans ctc-2 gene Proteins 0.000 description 10
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 10
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 10
- 101150000187 PTGS2 gene Proteins 0.000 description 10
- 230000035572 chemosensitivity Effects 0.000 description 10
- 238000002512 chemotherapy Methods 0.000 description 10
- 239000000975 dye Substances 0.000 description 10
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 9
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 9
- 229960004316 cisplatin Drugs 0.000 description 9
- 238000001514 detection method Methods 0.000 description 9
- 238000011160 research Methods 0.000 description 9
- 201000009030 Carcinoma Diseases 0.000 description 8
- 206010027476 Metastases Diseases 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- 238000003757 reverse transcription PCR Methods 0.000 description 8
- 208000009956 adenocarcinoma Diseases 0.000 description 7
- 238000002372 labelling Methods 0.000 description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- 230000000340 anti-metabolite Effects 0.000 description 6
- 229940100197 antimetabolite Drugs 0.000 description 6
- 239000002256 antimetabolite Substances 0.000 description 6
- 229940127093 camptothecin Drugs 0.000 description 6
- 210000001165 lymph node Anatomy 0.000 description 6
- 230000009401 metastasis Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 238000003752 polymerase chain reaction Methods 0.000 description 6
- 238000013518 transcription Methods 0.000 description 6
- 230000035897 transcription Effects 0.000 description 6
- 108091034117 Oligonucleotide Proteins 0.000 description 5
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 229960004679 doxorubicin Drugs 0.000 description 5
- 239000007850 fluorescent dye Substances 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 229960004857 mitomycin Drugs 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 4
- 230000033616 DNA repair Effects 0.000 description 4
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 4
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 4
- 108091060211 Expressed sequence tag Proteins 0.000 description 4
- 229930012538 Paclitaxel Natural products 0.000 description 4
- 229940122803 Vinca alkaloid Drugs 0.000 description 4
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 4
- 238000009098 adjuvant therapy Methods 0.000 description 4
- 230000004075 alteration Effects 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000012790 confirmation Methods 0.000 description 4
- 230000002596 correlated effect Effects 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 229960003668 docetaxel Drugs 0.000 description 4
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 201000005249 lung adenocarcinoma Diseases 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 229960001592 paclitaxel Drugs 0.000 description 4
- 230000001124 posttranscriptional effect Effects 0.000 description 4
- 238000004886 process control Methods 0.000 description 4
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 4
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 4
- 210000003932 urinary bladder Anatomy 0.000 description 4
- 238000010200 validation analysis Methods 0.000 description 4
- 238000000018 DNA microarray Methods 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 3
- 229940123237 Taxane Drugs 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 238000011226 adjuvant chemotherapy Methods 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- ZWAOHEXOSAUJHY-ZIYNGMLESA-N doxifluridine Chemical compound O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ZWAOHEXOSAUJHY-ZIYNGMLESA-N 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- -1 etc) Proteins 0.000 description 3
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 3
- 229960005420 etoposide Drugs 0.000 description 3
- 229960005277 gemcitabine Drugs 0.000 description 3
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 229940079322 interferon Drugs 0.000 description 3
- 229960004768 irinotecan Drugs 0.000 description 3
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 230000036210 malignancy Effects 0.000 description 3
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 230000009456 molecular mechanism Effects 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 230000002018 overexpression Effects 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- LLTDOAPVRPZLCM-UHFFFAOYSA-O 4-(7,8,8,16,16,17-hexamethyl-4,20-disulfo-2-oxa-18-aza-6-azoniapentacyclo[11.7.0.03,11.05,9.015,19]icosa-1(20),3,5,9,11,13,15(19)-heptaen-12-yl)benzoic acid Chemical compound CC1(C)C(C)NC(C(=C2OC3=C(C=4C(C(C(C)[NH+]=4)(C)C)=CC3=3)S(O)(=O)=O)S(O)(=O)=O)=C1C=C2C=3C1=CC=C(C(O)=O)C=C1 LLTDOAPVRPZLCM-UHFFFAOYSA-O 0.000 description 2
- NJYVEMPWNAYQQN-UHFFFAOYSA-N 5-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C21OC(=O)C1=CC(C(=O)O)=CC=C21 NJYVEMPWNAYQQN-UHFFFAOYSA-N 0.000 description 2
- WQZIDRAQTRIQDX-UHFFFAOYSA-N 6-carboxy-x-rhodamine Chemical compound OC(=O)C1=CC=C(C([O-])=O)C=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 WQZIDRAQTRIQDX-UHFFFAOYSA-N 0.000 description 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 2
- 208000003200 Adenoma Diseases 0.000 description 2
- 206010001233 Adenoma benign Diseases 0.000 description 2
- 201000004384 Alopecia Diseases 0.000 description 2
- 206010059313 Anogenital warts Diseases 0.000 description 2
- 108020005544 Antisense RNA Proteins 0.000 description 2
- 102100021986 Apoptosis-stimulating of p53 protein 2 Human genes 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
- 108010092160 Dactinomycin Proteins 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 101000752711 Homo sapiens Apoptosis-stimulating of p53 protein 2 Proteins 0.000 description 2
- 101000605528 Homo sapiens Kallikrein-2 Proteins 0.000 description 2
- 101000605534 Homo sapiens Prostate-specific antigen Proteins 0.000 description 2
- 101001001272 Homo sapiens Prostatic acid phosphatase Proteins 0.000 description 2
- 101000873502 Homo sapiens S-adenosylmethionine decarboxylase proenzyme Proteins 0.000 description 2
- 102000006992 Interferon-alpha Human genes 0.000 description 2
- 108010047761 Interferon-alpha Proteins 0.000 description 2
- 102000003996 Interferon-beta Human genes 0.000 description 2
- 108090000467 Interferon-beta Proteins 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 102100038356 Kallikrein-2 Human genes 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 2
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 102100038358 Prostate-specific antigen Human genes 0.000 description 2
- 102100035703 Prostatic acid phosphatase Human genes 0.000 description 2
- 108091034057 RNA (poly(A)) Proteins 0.000 description 2
- 108010041388 Ribonucleotide Reductases Proteins 0.000 description 2
- 102000000505 Ribonucleotide Reductases Human genes 0.000 description 2
- 102100035914 S-adenosylmethionine decarboxylase proenzyme Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 229940045799 anthracyclines and related substance Drugs 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 2
- 238000005251 capillar electrophoresis Methods 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 239000003184 complementary RNA Substances 0.000 description 2
- 238000002790 cross-validation Methods 0.000 description 2
- 229960000684 cytarabine Drugs 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 229960000640 dactinomycin Drugs 0.000 description 2
- 229960000975 daunorubicin Drugs 0.000 description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
- 238000000151 deposition Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 201000010063 epididymitis Diseases 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 238000001917 fluorescence detection Methods 0.000 description 2
- 238000001215 fluorescent labelling Methods 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 2
- 229960002411 imatinib Drugs 0.000 description 2
- 201000001881 impotence Diseases 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 229960003130 interferon gamma Drugs 0.000 description 2
- 229960001388 interferon-beta Drugs 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229960001428 mercaptopurine Drugs 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000009099 neoadjuvant therapy Methods 0.000 description 2
- 238000007899 nucleic acid hybridization Methods 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 238000010837 poor prognosis Methods 0.000 description 2
- 238000007781 pre-processing Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108010090388 progesterone receptor A Proteins 0.000 description 2
- 108010090371 progesterone receptor B Proteins 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 208000023958 prostate neoplasm Diseases 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000000009 pyrolysis mass spectrometry Methods 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 230000022983 regulation of cell cycle Effects 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 108020004418 ribosomal RNA Proteins 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 2
- 229960003087 tioguanine Drugs 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 238000000539 two dimensional gel electrophoresis Methods 0.000 description 2
- 210000000626 ureter Anatomy 0.000 description 2
- 229960003048 vinblastine Drugs 0.000 description 2
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 2
- 229960004528 vincristine Drugs 0.000 description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- 101150084750 1 gene Proteins 0.000 description 1
- 102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 description 1
- 101150028074 2 gene Proteins 0.000 description 1
- UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 1
- 101150090724 3 gene Proteins 0.000 description 1
- 101150033839 4 gene Proteins 0.000 description 1
- DEQPBRIACBATHE-FXQIFTODSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-2-iminopentanoic acid Chemical compound N1C(=O)N[C@@H]2[C@H](CCCC(=N)C(=O)O)SC[C@@H]21 DEQPBRIACBATHE-FXQIFTODSA-N 0.000 description 1
- 231100000582 ATP assay Toxicity 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 206010068625 Acquired phimosis Diseases 0.000 description 1
- 206010000599 Acromegaly Diseases 0.000 description 1
- 208000000197 Acute Cholecystitis Diseases 0.000 description 1
- 208000026872 Addison Disease Diseases 0.000 description 1
- 208000005641 Adenomyosis Diseases 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 102100032187 Androgen receptor Human genes 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 241000219194 Arabidopsis Species 0.000 description 1
- YZXBAPSDXZZRGB-DOFZRALJSA-M Arachidonate Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC([O-])=O YZXBAPSDXZZRGB-DOFZRALJSA-M 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000004746 Atrophic Vaginitis Diseases 0.000 description 1
- 206010003693 Atrophic vulvovaginitis Diseases 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 1
- 102100032311 Aurora kinase A Human genes 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 108700020463 BRCA1 Proteins 0.000 description 1
- 102000036365 BRCA1 Human genes 0.000 description 1
- 101150072950 BRCA1 gene Proteins 0.000 description 1
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 description 1
- 206010004078 Balanoposthitis Diseases 0.000 description 1
- 208000023666 Bartholin abscess Diseases 0.000 description 1
- 101150017888 Bcl2 gene Proteins 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 206010006143 Brain stem glioma Diseases 0.000 description 1
- 206010006326 Breath odour Diseases 0.000 description 1
- 102100032912 CD44 antigen Human genes 0.000 description 1
- 108091007914 CDKs Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102100033086 Calcium/calmodulin-dependent protein kinase type 1 Human genes 0.000 description 1
- 102000000584 Calmodulin Human genes 0.000 description 1
- 108010041952 Calmodulin Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 206010007558 Cardiac failure chronic Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 208000014882 Carotid artery disease Diseases 0.000 description 1
- 206010008254 Cervical cyst Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 206010008614 Cholecystitis acute Diseases 0.000 description 1
- 206010008690 Chondrocalcinosis pyrophosphate Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 108020004394 Complementary RNA Proteins 0.000 description 1
- 208000000907 Condylomata Acuminata Diseases 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 208000008953 Cryptosporidiosis Diseases 0.000 description 1
- 206010011502 Cryptosporidiosis infection Diseases 0.000 description 1
- 208000014311 Cushing syndrome Diseases 0.000 description 1
- 108050006400 Cyclin Proteins 0.000 description 1
- 102000016736 Cyclin Human genes 0.000 description 1
- 102100033270 Cyclin-dependent kinase inhibitor 1 Human genes 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 201000010374 Down Syndrome Diseases 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 208000004483 Dyspareunia Diseases 0.000 description 1
- 101150029707 ERBB2 gene Proteins 0.000 description 1
- 208000030814 Eating disease Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 102100029987 Erbin Human genes 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 102100038595 Estrogen receptor Human genes 0.000 description 1
- 208000034347 Faecal incontinence Diseases 0.000 description 1
- 208000019454 Feeding and Eating disease Diseases 0.000 description 1
- 206010057671 Female sexual dysfunction Diseases 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- 238000008416 Ferritin Methods 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 206010016845 Foetal alcohol syndrome Diseases 0.000 description 1
- 206010016936 Folliculitis Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 101150052409 GRB7 gene Proteins 0.000 description 1
- 241000207201 Gardnerella vaginalis Species 0.000 description 1
- 206010061968 Gastric neoplasm Diseases 0.000 description 1
- 206010018143 Genital candidiasis Diseases 0.000 description 1
- 206010056740 Genital discharge Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 208000022461 Glomerular disease Diseases 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 102100031150 Growth arrest and DNA damage-inducible protein GADD45 alpha Human genes 0.000 description 1
- 206010056438 Growth hormone deficiency Diseases 0.000 description 1
- 208000025309 Hair disease Diseases 0.000 description 1
- 208000032139 Halitosis Diseases 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 208000001688 Herpes Genitalis Diseases 0.000 description 1
- 206010019973 Herpes virus infection Diseases 0.000 description 1
- 102100022128 High mobility group protein B2 Human genes 0.000 description 1
- 101710168540 High mobility group protein B2 Proteins 0.000 description 1
- 108090000246 Histone acetyltransferases Proteins 0.000 description 1
- 102000003893 Histone acetyltransferases Human genes 0.000 description 1
- 102100030231 Homeobox protein cut-like 2 Human genes 0.000 description 1
- 102000009331 Homeodomain Proteins Human genes 0.000 description 1
- 108010048671 Homeodomain Proteins Proteins 0.000 description 1
- 101000798300 Homo sapiens Aurora kinase A Proteins 0.000 description 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
- 101000944250 Homo sapiens Calcium/calmodulin-dependent protein kinase type 1 Proteins 0.000 description 1
- 101000944380 Homo sapiens Cyclin-dependent kinase inhibitor 1 Proteins 0.000 description 1
- 101001010810 Homo sapiens Erbin Proteins 0.000 description 1
- 101001066158 Homo sapiens Growth arrest and DNA damage-inducible protein GADD45 alpha Proteins 0.000 description 1
- 101000726714 Homo sapiens Homeobox protein cut-like 2 Proteins 0.000 description 1
- 101001044094 Homo sapiens Inositol monophosphatase 2 Proteins 0.000 description 1
- 101001044940 Homo sapiens Insulin-like growth factor-binding protein 2 Proteins 0.000 description 1
- 101001006789 Homo sapiens Kinesin heavy chain isoform 5C Proteins 0.000 description 1
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 description 1
- 101000628547 Homo sapiens Metalloreductase STEAP1 Proteins 0.000 description 1
- 101000973405 Homo sapiens Nuclear transcription factor Y subunit beta Proteins 0.000 description 1
- 101001098930 Homo sapiens Pachytene checkpoint protein 2 homolog Proteins 0.000 description 1
- 101000691783 Homo sapiens Pirin Proteins 0.000 description 1
- 101100140242 Homo sapiens RDH11 gene Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 101000777293 Homo sapiens Serine/threonine-protein kinase Chk1 Proteins 0.000 description 1
- 101000946167 Homo sapiens Transcription factor LBX1 Proteins 0.000 description 1
- 201000002980 Hyperparathyroidism Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 206010058359 Hypogonadism Diseases 0.000 description 1
- 206010021067 Hypopituitarism Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 208000029836 Inguinal Hernia Diseases 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 102100021608 Inositol monophosphatase 2 Human genes 0.000 description 1
- 102100022710 Insulin-like growth factor-binding protein 2 Human genes 0.000 description 1
- 206010022562 Intermittent claudication Diseases 0.000 description 1
- 206010022678 Intestinal infections Diseases 0.000 description 1
- 206010061252 Intraocular melanoma Diseases 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 238000010824 Kaplan-Meier survival analysis Methods 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 102100027928 Kinesin heavy chain isoform 5C Human genes 0.000 description 1
- 206010061523 Lip and/or oral cavity cancer Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 239000007987 MES buffer Substances 0.000 description 1
- 102100025136 Macrosialin Human genes 0.000 description 1
- 208000035771 Malignant Sertoli-Leydig cell tumor of the ovary Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 241001599018 Melanogaster Species 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 102100026712 Metalloreductase STEAP1 Human genes 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 108700019961 Neoplasm Genes Proteins 0.000 description 1
- 102000048850 Neoplasm Genes Human genes 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 208000009905 Neurofibromatoses Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 101710205482 Nuclear factor 1 A-type Proteins 0.000 description 1
- 102100024006 Nuclear factor 1 A-type Human genes 0.000 description 1
- 102100022201 Nuclear transcription factor Y subunit beta Human genes 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 208000012898 Olfaction disease Diseases 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000005141 Otitis Diseases 0.000 description 1
- 206010033314 Ovulation pain Diseases 0.000 description 1
- 102100029181 PDZ and LIM domain protein 5 Human genes 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102100038993 Pachytene checkpoint protein 2 homolog Human genes 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000037158 Partial Epilepsies Diseases 0.000 description 1
- 206010061334 Partial seizures Diseases 0.000 description 1
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 1
- 208000004362 Penile Induration Diseases 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 102000002508 Peptide Elongation Factors Human genes 0.000 description 1
- 108010068204 Peptide Elongation Factors Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 108091093037 Peptide nucleic acid Proteins 0.000 description 1
- 208000020758 Peyronie disease Diseases 0.000 description 1
- 102100026123 Pirin Human genes 0.000 description 1
- 102000004576 Placental Lactogen Human genes 0.000 description 1
- 108010003044 Placental Lactogen Proteins 0.000 description 1
- 239000000381 Placental Lactogen Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 206010036297 Postpartum hypopituitarism Diseases 0.000 description 1
- YWYQTGBBEZQBGO-BERLURQNSA-N Pregnanediol Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](O)C)[C@@]2(C)CC1 YWYQTGBBEZQBGO-BERLURQNSA-N 0.000 description 1
- 206010036618 Premenstrual syndrome Diseases 0.000 description 1
- 206010036832 Prolactinoma Diseases 0.000 description 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108010026552 Proteome Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 108020004518 RNA Probes Proteins 0.000 description 1
- 239000003391 RNA probe Substances 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 102000002490 Rad51 Recombinase Human genes 0.000 description 1
- 108010068097 Rad51 Recombinase Proteins 0.000 description 1
- 238000001069 Raman spectroscopy Methods 0.000 description 1
- 108090000244 Rat Proteins Proteins 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 108700025701 Retinoblastoma Genes Proteins 0.000 description 1
- 102100023916 Retinol dehydrogenase 11 Human genes 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 102000002278 Ribosomal Proteins Human genes 0.000 description 1
- 108010000605 Ribosomal Proteins Proteins 0.000 description 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 1
- 206010061934 Salivary gland cancer Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- 102100031081 Serine/threonine-protein kinase Chk1 Human genes 0.000 description 1
- 208000000097 Sertoli-Leydig cell tumor Diseases 0.000 description 1
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 1
- 208000019802 Sexually transmitted disease Diseases 0.000 description 1
- 201000009895 Sheehan syndrome Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010041235 Snoring Diseases 0.000 description 1
- 206010041250 Social phobia Diseases 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 201000010829 Spina bifida Diseases 0.000 description 1
- 208000006097 Spinal Dysraphism Diseases 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 108010002687 Survivin Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 102000005497 Thymidylate Synthase Human genes 0.000 description 1
- 208000024799 Thyroid disease Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 208000010641 Tooth disease Diseases 0.000 description 1
- 102100034738 Transcription factor LBX1 Human genes 0.000 description 1
- 208000005448 Trichomonas Infections Diseases 0.000 description 1
- 206010044620 Trichomoniasis Diseases 0.000 description 1
- YWYQTGBBEZQBGO-UHFFFAOYSA-N UC1011 Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(O)C)C1(C)CC2 YWYQTGBBEZQBGO-UHFFFAOYSA-N 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010064996 Ulcerative keratitis Diseases 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- 208000006593 Urologic Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 206010046798 Uterine leiomyoma Diseases 0.000 description 1
- 201000005969 Uveal melanoma Diseases 0.000 description 1
- 206010046900 Vaginal cyst Diseases 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 description 1
- 208000003728 Vulvodynia Diseases 0.000 description 1
- 201000007096 Vulvovaginal Candidiasis Diseases 0.000 description 1
- 206010069055 Vulvovaginal pain Diseases 0.000 description 1
- 101150005599 XXX gene Proteins 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000011446 adjuvant hormonal therapy Methods 0.000 description 1
- 238000011366 aggressive therapy Methods 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000002669 amniocentesis Methods 0.000 description 1
- 238000000631 analytical pyrolysis Methods 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 108010080146 androgen receptors Proteins 0.000 description 1
- 208000025009 anogenital human papillomavirus infection Diseases 0.000 description 1
- 201000004201 anogenital venereal wart Diseases 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229940114078 arachidonate Drugs 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 238000013528 artificial neural network Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 1
- 238000013475 authorization Methods 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000008236 biological pathway Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 208000028683 bipolar I disease Diseases 0.000 description 1
- 230000007698 birth defect Effects 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 108010083912 bleomycin N-acetyltransferase Proteins 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 208000030270 breast disease Diseases 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 230000005773 cancer-related death Effects 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 238000013172 carotid endarterectomy Methods 0.000 description 1
- 208000003295 carpal tunnel syndrome Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 206010008129 cerebral palsy Diseases 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 201000004308 chancroid Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000012569 chemometric method Methods 0.000 description 1
- 238000009104 chemotherapy regimen Methods 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- 208000002849 chondrocalcinosis Diseases 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
- 208000024980 claudication Diseases 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 230000004732 colorectal carcinogenesis Effects 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 208000021921 corneal disease Diseases 0.000 description 1
- 201000007717 corneal ulcer Diseases 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 238000002574 cystoscopy Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000007418 data mining Methods 0.000 description 1
- 238000013500 data storage Methods 0.000 description 1
- 208000012208 de Quervain disease Diseases 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010064 diabetes insipidus Diseases 0.000 description 1
- 230000009699 differential effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 208000034653 disorder of pilosebaceous unit Diseases 0.000 description 1
- 235000014632 disordered eating Nutrition 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 229950005454 doxifluridine Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 208000019258 ear infection Diseases 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 201000009274 endometriosis of uterus Diseases 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 208000024519 eye neoplasm Diseases 0.000 description 1
- 208000026934 fetal alcohol spectrum disease Diseases 0.000 description 1
- 201000007794 fetal alcohol syndrome Diseases 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 102000003684 fibroblast growth factor 13 Human genes 0.000 description 1
- 108090000047 fibroblast growth factor 13 Proteins 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 201000007186 focal epilepsy Diseases 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000012224 gene deletion Methods 0.000 description 1
- 238000011223 gene expression profiling Methods 0.000 description 1
- 201000004946 genital herpes Diseases 0.000 description 1
- 208000004104 gestational diabetes Diseases 0.000 description 1
- 208000024693 gingival disease Diseases 0.000 description 1
- 231100000852 glomerular disease Toxicity 0.000 description 1
- 201000003872 goiter Diseases 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 208000037824 growth disorder Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 235000015220 hamburgers Nutrition 0.000 description 1
- 108060003552 hemocyanin Proteins 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 206010021093 hypospadias Diseases 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 238000009802 hysterectomy Methods 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000007641 inkjet printing Methods 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 208000030776 invasive breast carcinoma Diseases 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 238000010801 machine learning Methods 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 208000007106 menorrhagia Diseases 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 208000010658 metastatic prostate carcinoma Diseases 0.000 description 1
- 238000004452 microanalysis Methods 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 238000012543 microbiological analysis Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000000329 molecular dynamics simulation Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 238000000491 multivariate analysis Methods 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 208000016369 nabothian cyst Diseases 0.000 description 1
- 201000003631 narcolepsy Diseases 0.000 description 1
- 208000018795 nasal cavity and paranasal sinus carcinoma Diseases 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 239000006225 natural substrate Substances 0.000 description 1
- 201000004931 neurofibromatosis Diseases 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 201000008106 ocular cancer Diseases 0.000 description 1
- 201000002575 ocular melanoma Diseases 0.000 description 1
- 238000002966 oligonucleotide array Methods 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 201000005737 orchitis Diseases 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 208000012221 ovarian Sertoli-Leydig cell tumor Diseases 0.000 description 1
- 208000025661 ovarian cyst Diseases 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 208000009291 paraphimosis Diseases 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 206010049430 peripartum cardiomyopathy Diseases 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000002974 pharmacogenomic effect Effects 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 201000010808 postmenopausal atrophic vaginitis Diseases 0.000 description 1
- 201000011461 pre-eclampsia Diseases 0.000 description 1
- 201000011264 priapism Diseases 0.000 description 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 208000030153 prolactin-producing pituitary gland adenoma Diseases 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 238000011155 quantitative monitoring Methods 0.000 description 1
- 238000009801 radical cystectomy Methods 0.000 description 1
- 238000011127 radiochemotherapy Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 208000016691 refractory malignant neoplasm Diseases 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000012340 reverse transcriptase PCR Methods 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- 238000002416 scanning tunnelling spectroscopy Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 208000011581 secondary neoplasm Diseases 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 235000019561 smell disorders Nutrition 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 206010062261 spinal cord neoplasm Diseases 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000012706 support-vector machine Methods 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 208000011317 telomere syndrome Diseases 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 208000021510 thyroid gland disease Diseases 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 230000006663 ubiquitin-proteasome pathway Effects 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 206010046885 vaginal cancer Diseases 0.000 description 1
- 208000013139 vaginal neoplasm Diseases 0.000 description 1
- 208000010484 vulvovaginitis Diseases 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
- G06N7/00—Computing arrangements based on specific mathematical models
- G06N7/01—Probabilistic graphical models, e.g. probabilistic networks
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
- G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16B40/20—Supervised data analysis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
- G16B25/30—Microarray design
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/954,443 US20050071087A1 (en) | 2003-09-29 | 2004-09-29 | Systems and methods for detecting biological features |
US13/418,991 US8977506B2 (en) | 2003-09-29 | 2012-03-13 | Systems and methods for detecting biological features |
US14/624,453 US20150161327A1 (en) | 2003-09-29 | 2015-02-17 | Systems and methods for detecting biological features |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US50738103P | 2003-09-29 | 2003-09-29 | |
US50744503P | 2003-09-29 | 2003-09-29 | |
US10/861,177 US8321137B2 (en) | 2003-09-29 | 2004-06-04 | Knowledge-based storage of diagnostic models |
US10/861,216 US20050069863A1 (en) | 2003-09-29 | 2004-06-04 | Systems and methods for analyzing gene expression data for clinical diagnostics |
US57741604P | 2004-06-05 | 2004-06-05 | |
US10/954,443 US20050071087A1 (en) | 2003-09-29 | 2004-09-29 | Systems and methods for detecting biological features |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/861,216 Continuation-In-Part US20050069863A1 (en) | 2003-09-29 | 2004-06-04 | Systems and methods for analyzing gene expression data for clinical diagnostics |
US10/861,177 Continuation-In-Part US8321137B2 (en) | 2003-09-29 | 2004-06-04 | Knowledge-based storage of diagnostic models |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/418,991 Continuation US8977506B2 (en) | 2003-09-29 | 2012-03-13 | Systems and methods for detecting biological features |
Publications (1)
Publication Number | Publication Date |
---|---|
US20050071087A1 true US20050071087A1 (en) | 2005-03-31 |
Family
ID=34382268
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/954,443 Abandoned US20050071087A1 (en) | 2003-09-29 | 2004-09-29 | Systems and methods for detecting biological features |
US13/418,991 Expired - Fee Related US8977506B2 (en) | 2003-09-29 | 2012-03-13 | Systems and methods for detecting biological features |
US14/624,453 Abandoned US20150161327A1 (en) | 2003-09-29 | 2015-02-17 | Systems and methods for detecting biological features |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/418,991 Expired - Fee Related US8977506B2 (en) | 2003-09-29 | 2012-03-13 | Systems and methods for detecting biological features |
US14/624,453 Abandoned US20150161327A1 (en) | 2003-09-29 | 2015-02-17 | Systems and methods for detecting biological features |
Country Status (8)
Country | Link |
---|---|
US (3) | US20050071087A1 (ja) |
EP (2) | EP1671121A4 (ja) |
JP (2) | JP2007507770A (ja) |
KR (1) | KR20060120063A (ja) |
AU (1) | AU2004285103A1 (ja) |
CA (1) | CA2540167A1 (ja) |
IL (1) | IL174599A0 (ja) |
WO (1) | WO2005042760A2 (ja) |
Cited By (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050069863A1 (en) * | 2003-09-29 | 2005-03-31 | Jorge Moraleda | Systems and methods for analyzing gene expression data for clinical diagnostics |
US20050071143A1 (en) * | 2003-09-29 | 2005-03-31 | Quang Tran | Knowledge-based storage of diagnostic models |
US20050256745A1 (en) * | 2004-05-14 | 2005-11-17 | Dalton William S | Computer systems and methods for providing health care |
US20060252082A1 (en) * | 2005-05-04 | 2006-11-09 | University Of South Florida | Predicting treatment response in cancer subjects |
CN101329348A (zh) * | 2007-06-18 | 2008-12-24 | 许洋 | 检测胃癌特征蛋白的优化质谱模型及其制备方法和应用 |
US20090017012A1 (en) * | 2007-06-15 | 2009-01-15 | University Of South Florida | Methods of diagnosing and treating cancer |
WO2009035946A1 (en) * | 2007-09-13 | 2009-03-19 | Chemimage Corporation | Distinguishing between invasive ductal carcinoma and invasive lobular carcinoma using raman molecular imaging |
WO2009035942A1 (en) * | 2007-09-13 | 2009-03-19 | Chemimage Corporation | Distinguishing between renal oncocytoma and chromophobe renal cell carcinoma using raman molecular imaging |
US20110004412A1 (en) * | 2007-11-29 | 2011-01-06 | Elminda Ltd. | Clinical applications of neuropsychological pattern analysis and modeling |
US20110022548A1 (en) * | 2007-02-05 | 2011-01-27 | Goded Shahaf | System and method for neural modeling of neurophysiological data |
GB2479058A (en) * | 2010-03-24 | 2011-09-28 | Nodality Inc | Modeling biological events |
US20120109678A1 (en) * | 2009-05-11 | 2012-05-03 | Koninklijke Philips Electronics N.V. | Device and method for comparing molecular signatures |
US20130337444A1 (en) * | 2012-05-22 | 2013-12-19 | Nanostring Technologies, Inc. | NANO46 Genes and Methods to Predict Breast Cancer Outcome |
US20150221105A1 (en) * | 2012-08-30 | 2015-08-06 | Truevision Systems, Inc. | Imaging system and methods displaying a fused multidimensional reconstructed image |
US9135221B2 (en) | 2006-05-25 | 2015-09-15 | Elminda Ltd. | Neuropsychological spatiotemporal pattern recognition |
US9285577B2 (en) | 2010-09-30 | 2016-03-15 | Olympus Corporation | Microscope system and data distribution system |
US10117721B2 (en) | 2008-10-10 | 2018-11-06 | Truevision Systems, Inc. | Real-time surgical reference guides and methods for surgical applications |
US10299880B2 (en) | 2017-04-24 | 2019-05-28 | Truevision Systems, Inc. | Stereoscopic visualization camera and platform |
US10398598B2 (en) | 2008-04-04 | 2019-09-03 | Truevision Systems, Inc. | Apparatus and methods for performing enhanced visually directed procedures under low ambient light conditions |
US10917543B2 (en) | 2017-04-24 | 2021-02-09 | Alcon Inc. | Stereoscopic visualization camera and integrated robotics platform |
US11039901B2 (en) | 2009-02-20 | 2021-06-22 | Alcon, Inc. | Real-time surgical reference indicium apparatus and methods for intraocular lens implantation |
US11051884B2 (en) | 2008-10-10 | 2021-07-06 | Alcon, Inc. | Real-time surgical reference indicium apparatus and methods for surgical applications |
US11083537B2 (en) | 2017-04-24 | 2021-08-10 | Alcon Inc. | Stereoscopic camera with fluorescence visualization |
US11527323B2 (en) | 2019-05-14 | 2022-12-13 | Tempus Labs, Inc. | Systems and methods for multi-label cancer classification |
US11735302B2 (en) | 2021-06-10 | 2023-08-22 | Alife Health Inc. | Machine learning for optimizing ovarian stimulation |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005042760A2 (en) | 2003-09-29 | 2005-05-12 | Pathwork Informatics, Inc. | Systems and methods for detecting biological features |
US8784443B2 (en) | 2009-10-20 | 2014-07-22 | Truevision Systems, Inc. | Real-time surgical reference indicium apparatus and methods for astigmatism correction |
JP6164135B2 (ja) * | 2014-03-27 | 2017-07-19 | 株式会社豊田自動織機 | 圧縮機 |
FR3024546B1 (fr) * | 2014-07-29 | 2018-08-24 | Universite De Reims Champagne-Ardenne | Procede de detection et de quantification de la fibrose |
CN111639203B (zh) * | 2020-05-28 | 2023-07-07 | 神华包神铁路集团有限责任公司 | 隧道病害定位方法、装置、计算机设备和存储介质 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6344316B1 (en) * | 1996-01-23 | 2002-02-05 | Affymetrix, Inc. | Nucleic acid analysis techniques |
US6389305B1 (en) * | 1993-12-15 | 2002-05-14 | Lifeline Biotechnologies, Inc. | Method and apparatus for detection of cancerous and precancerous conditions in a breast |
US7774143B2 (en) * | 2002-04-25 | 2010-08-10 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Methods for analyzing high dimensional data for classifying, diagnosing, prognosticating, and/or predicting diseases and other biological states |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
US5545522A (en) | 1989-09-22 | 1996-08-13 | Van Gelder; Russell N. | Process for amplifying a target polynucleotide sequence using a single primer-promoter complex |
DE69233719T2 (de) | 1991-09-24 | 2009-01-02 | Keygene N.V. | Primer, Sätze und Restriktionsfragmente und deren Benutzung in selektiver Restriktionsfragmentenamplifikation |
US5578832A (en) | 1994-09-02 | 1996-11-26 | Affymetrix, Inc. | Method and apparatus for imaging a sample on a device |
US5539083A (en) | 1994-02-23 | 1996-07-23 | Isis Pharmaceuticals, Inc. | Peptide nucleic acid combinatorial libraries and improved methods of synthesis |
US5989811A (en) | 1994-09-29 | 1999-11-23 | Urocor, Inc. | Sextant core biopsy predictive mechanism for non-organ confined disease status |
US5556752A (en) | 1994-10-24 | 1996-09-17 | Affymetrix, Inc. | Surface-bound, unimolecular, double-stranded DNA |
US6303301B1 (en) | 1997-01-13 | 2001-10-16 | Affymetrix, Inc. | Expression monitoring for gene function identification |
US6028189A (en) | 1997-03-20 | 2000-02-22 | University Of Washington | Solvent for oligonucleotide synthesis and methods of use |
US6384210B1 (en) | 1997-03-20 | 2002-05-07 | University Of Washington | Solvent for biopolymer synthesis, solvent microdroplets and methods of use |
US6420108B2 (en) | 1998-02-09 | 2002-07-16 | Affymetrix, Inc. | Computer-aided display for comparative gene expression |
US6912524B2 (en) | 1998-05-20 | 2005-06-28 | Lucent Technologies, Inc. | Join synopsis-based approximate query answering |
US6468476B1 (en) | 1998-10-27 | 2002-10-22 | Rosetta Inpharmatics, Inc. | Methods for using-co-regulated genesets to enhance detection and classification of gene expression patterns |
US6263287B1 (en) | 1998-11-12 | 2001-07-17 | Scios Inc. | Systems for the analysis of gene expression data |
US6453241B1 (en) | 1998-12-23 | 2002-09-17 | Rosetta Inpharmatics, Inc. | Method and system for analyzing biological response signal data |
US6351712B1 (en) | 1998-12-28 | 2002-02-26 | Rosetta Inpharmatics, Inc. | Statistical combining of cell expression profiles |
CA2300639A1 (en) | 1999-03-15 | 2000-09-15 | Whitehead Institute For Biomedical Research | Methods and apparatus for analyzing gene expression data |
US6647341B1 (en) | 1999-04-09 | 2003-11-11 | Whitehead Institute For Biomedical Research | Methods for classifying samples and ascertaining previously unknown classes |
US7324926B2 (en) | 1999-04-09 | 2008-01-29 | Whitehead Institute For Biomedical Research | Methods for predicting chemosensitivity or chemoresistance |
US6502039B1 (en) | 2000-05-24 | 2002-12-31 | Aventis Pharmaceuticals | Mathematical analysis for the estimation of changes in the level of gene expression |
US6132997A (en) | 1999-05-28 | 2000-10-17 | Agilent Technologies | Method for linear mRNA amplification |
US6505125B1 (en) | 1999-09-28 | 2003-01-07 | Affymetrix, Inc. | Methods and computer software products for multiple probe gene expression analysis |
US6271002B1 (en) | 1999-10-04 | 2001-08-07 | Rosetta Inpharmatics, Inc. | RNA amplification method |
US20010049393A1 (en) | 1999-12-07 | 2001-12-06 | Whitehead Institute For Biomedical Research | Methods for defining MYC target genes and uses thereof |
EP1274463A2 (en) | 1999-12-10 | 2003-01-15 | Whitehead Institute For Biomedical Research | Metastasis genes and uses thereof |
JP2002063278A (ja) * | 2000-08-22 | 2002-02-28 | Shotaro Katsuki | 健康度評価システム及びその記録媒体並びに健康度評価方法 |
EP1339872A2 (en) | 2000-09-19 | 2003-09-03 | Whitehead Institute For Biomedical Research | Genetic markers for tumors |
US20030194701A1 (en) | 2000-11-20 | 2003-10-16 | Golub Todd R. | Diffuse large cell lymphoma diagnosis and outcome prediction by expression analysis |
WO2002059373A2 (en) | 2001-01-23 | 2002-08-01 | Irm, Llc | Genes overexpressed in prostate disorders as diagnostic and therapeutic targets |
US20020155480A1 (en) | 2001-01-31 | 2002-10-24 | Golub Todd R. | Brain tumor diagnosis and outcome prediction |
US6832069B2 (en) * | 2001-04-20 | 2004-12-14 | Educational Testing Service | Latent property diagnosing procedure |
WO2002101357A2 (en) | 2001-06-10 | 2002-12-19 | Irm Llc | Molecular signatures of commonly fatal carcinomas |
US7171311B2 (en) | 2001-06-18 | 2007-01-30 | Rosetta Inpharmatics Llc | Methods of assigning treatment to breast cancer patients |
EP1417297A4 (en) | 2001-07-13 | 2007-08-22 | Whitehead Biomedical Inst | LEUCEMIGENES TRANSCRIPTION FACTORS |
WO2003008552A2 (en) | 2001-07-17 | 2003-01-30 | Whitehead Institute For Biomedical Research | Mll translocations specify a distinct gene expression profile, distinguishing a unique leukemia |
US20040110193A1 (en) | 2001-07-31 | 2004-06-10 | Gene Logic, Inc. | Methods for classification of biological data |
AU2002324881A1 (en) | 2001-09-05 | 2003-03-18 | Wesleyan University | Diagnostic and prognostic tests |
US7622260B2 (en) | 2001-09-05 | 2009-11-24 | The Brigham And Women's Hospital, Inc. | Diagnostic and prognostic tests |
AU2002343443A1 (en) | 2001-09-28 | 2003-04-14 | Whitehead Institute For Biomedical Research | Classification of lung carcinomas using gene expression analysis |
US20030225526A1 (en) | 2001-11-14 | 2003-12-04 | Golub Todd R. | Molecular cancer diagnosis using tumor gene expression signature |
US20040010481A1 (en) | 2001-12-07 | 2004-01-15 | Whitehead Institute For Biomedical Research | Time-dependent outcome prediction using neural networks |
US20040009495A1 (en) | 2001-12-07 | 2004-01-15 | Whitehead Institute For Biomedical Research | Methods and products related to drug screening using gene expression patterns |
US6949342B2 (en) | 2001-12-21 | 2005-09-27 | Whitehead Institute For Biomedical Research | Prostate cancer diagnosis and outcome prediction by expression analysis |
US20030215835A1 (en) | 2002-01-15 | 2003-11-20 | Zairen Sun | Differentially-regulated prostate cancer genes |
US20030211531A1 (en) | 2002-05-01 | 2003-11-13 | Irm Llc | Methods for discovering tumor biomarkers and diagnosing tumors |
US20040098367A1 (en) | 2002-08-06 | 2004-05-20 | Whitehead Institute For Biomedical Research | Across platform and multiple dataset molecular classification |
US8321137B2 (en) | 2003-09-29 | 2012-11-27 | Pathwork Diagnostics, Inc. | Knowledge-based storage of diagnostic models |
US20050069863A1 (en) | 2003-09-29 | 2005-03-31 | Jorge Moraleda | Systems and methods for analyzing gene expression data for clinical diagnostics |
WO2005042760A2 (en) | 2003-09-29 | 2005-05-12 | Pathwork Informatics, Inc. | Systems and methods for detecting biological features |
-
2004
- 2004-09-29 WO PCT/US2004/032006 patent/WO2005042760A2/en active Application Filing
- 2004-09-29 EP EP04816896A patent/EP1671121A4/en not_active Ceased
- 2004-09-29 EP EP11186729A patent/EP2469439A2/en not_active Withdrawn
- 2004-09-29 JP JP2006528327A patent/JP2007507770A/ja not_active Withdrawn
- 2004-09-29 CA CA002540167A patent/CA2540167A1/en not_active Abandoned
- 2004-09-29 AU AU2004285103A patent/AU2004285103A1/en not_active Abandoned
- 2004-09-29 US US10/954,443 patent/US20050071087A1/en not_active Abandoned
- 2004-09-29 KR KR1020067008396A patent/KR20060120063A/ko not_active Application Discontinuation
-
2006
- 2006-03-27 IL IL174599A patent/IL174599A0/en unknown
-
2012
- 2012-01-05 JP JP2012000820A patent/JP2012065674A/ja not_active Withdrawn
- 2012-03-13 US US13/418,991 patent/US8977506B2/en not_active Expired - Fee Related
-
2015
- 2015-02-17 US US14/624,453 patent/US20150161327A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6389305B1 (en) * | 1993-12-15 | 2002-05-14 | Lifeline Biotechnologies, Inc. | Method and apparatus for detection of cancerous and precancerous conditions in a breast |
US6344316B1 (en) * | 1996-01-23 | 2002-02-05 | Affymetrix, Inc. | Nucleic acid analysis techniques |
US7774143B2 (en) * | 2002-04-25 | 2010-08-10 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Methods for analyzing high dimensional data for classifying, diagnosing, prognosticating, and/or predicting diseases and other biological states |
Non-Patent Citations (1)
Title |
---|
Carlson et al. (Urology, 1998, 52(3), 455-461) * |
Cited By (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050069863A1 (en) * | 2003-09-29 | 2005-03-31 | Jorge Moraleda | Systems and methods for analyzing gene expression data for clinical diagnostics |
US20050071143A1 (en) * | 2003-09-29 | 2005-03-31 | Quang Tran | Knowledge-based storage of diagnostic models |
US8321137B2 (en) | 2003-09-29 | 2012-11-27 | Pathwork Diagnostics, Inc. | Knowledge-based storage of diagnostic models |
US20050256745A1 (en) * | 2004-05-14 | 2005-11-17 | Dalton William S | Computer systems and methods for providing health care |
US8219417B2 (en) * | 2004-05-14 | 2012-07-10 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Front end |
US8135595B2 (en) * | 2004-05-14 | 2012-03-13 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Computer systems and methods for providing health care |
US8131567B2 (en) * | 2004-05-14 | 2012-03-06 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Value network |
US20110276339A1 (en) * | 2004-05-14 | 2011-11-10 | H. Lee Moffitt Cancer And Research Institute, Inc. | Front end |
US20110276347A1 (en) * | 2004-05-14 | 2011-11-10 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Value network |
US20130164747A1 (en) * | 2005-05-04 | 2013-06-27 | University Of South Florida | Predicting Treatment Response in Cancer Subjects |
US20060252082A1 (en) * | 2005-05-04 | 2006-11-09 | University Of South Florida | Predicting treatment response in cancer subjects |
US9135221B2 (en) | 2006-05-25 | 2015-09-15 | Elminda Ltd. | Neuropsychological spatiotemporal pattern recognition |
US9730642B2 (en) | 2006-05-25 | 2017-08-15 | Elmina Ltd. | Neuropsychological spatiotemporal pattern recognition |
US20140214730A9 (en) * | 2007-02-05 | 2014-07-31 | Goded Shahaf | System and method for neural modeling of neurophysiological data |
US20110022548A1 (en) * | 2007-02-05 | 2011-01-27 | Goded Shahaf | System and method for neural modeling of neurophysiological data |
US20090017012A1 (en) * | 2007-06-15 | 2009-01-15 | University Of South Florida | Methods of diagnosing and treating cancer |
CN101329348A (zh) * | 2007-06-18 | 2008-12-24 | 许洋 | 检测胃癌特征蛋白的优化质谱模型及其制备方法和应用 |
WO2009035946A1 (en) * | 2007-09-13 | 2009-03-19 | Chemimage Corporation | Distinguishing between invasive ductal carcinoma and invasive lobular carcinoma using raman molecular imaging |
WO2009035942A1 (en) * | 2007-09-13 | 2009-03-19 | Chemimage Corporation | Distinguishing between renal oncocytoma and chromophobe renal cell carcinoma using raman molecular imaging |
US20110004412A1 (en) * | 2007-11-29 | 2011-01-06 | Elminda Ltd. | Clinical applications of neuropsychological pattern analysis and modeling |
US10398598B2 (en) | 2008-04-04 | 2019-09-03 | Truevision Systems, Inc. | Apparatus and methods for performing enhanced visually directed procedures under low ambient light conditions |
US11051884B2 (en) | 2008-10-10 | 2021-07-06 | Alcon, Inc. | Real-time surgical reference indicium apparatus and methods for surgical applications |
US10117721B2 (en) | 2008-10-10 | 2018-11-06 | Truevision Systems, Inc. | Real-time surgical reference guides and methods for surgical applications |
US11039901B2 (en) | 2009-02-20 | 2021-06-22 | Alcon, Inc. | Real-time surgical reference indicium apparatus and methods for intraocular lens implantation |
US20120109678A1 (en) * | 2009-05-11 | 2012-05-03 | Koninklijke Philips Electronics N.V. | Device and method for comparing molecular signatures |
US8924232B2 (en) * | 2009-05-11 | 2014-12-30 | Koninklijke Philips N.V. | Device and method for comparing molecular signatures |
GB2479058A (en) * | 2010-03-24 | 2011-09-28 | Nodality Inc | Modeling biological events |
US9285577B2 (en) | 2010-09-30 | 2016-03-15 | Olympus Corporation | Microscope system and data distribution system |
US20130337444A1 (en) * | 2012-05-22 | 2013-12-19 | Nanostring Technologies, Inc. | NANO46 Genes and Methods to Predict Breast Cancer Outcome |
US11386992B2 (en) * | 2012-08-30 | 2022-07-12 | Alcon Inc. | Imaging system and methods displaying a fused multidimensional reconstructed image |
US20220301693A1 (en) * | 2012-08-30 | 2022-09-22 | Alcon Inc. | Imaging system and methods displaying a fused multidimensional reconstructed image |
US9552660B2 (en) * | 2012-08-30 | 2017-01-24 | Truevision Systems, Inc. | Imaging system and methods displaying a fused multidimensional reconstructed image |
US10740933B2 (en) * | 2012-08-30 | 2020-08-11 | Alcon Inc. | Imaging system and methods displaying a fused multidimensional reconstructed image |
US11682483B2 (en) * | 2012-08-30 | 2023-06-20 | Alcon Inc. | Imaging system and methods displaying a fused multidimensional reconstructed image |
US20180322666A1 (en) * | 2012-08-30 | 2018-11-08 | Truevision Systems, Inc. | Imaging system and methods displaying a fused multidimensional reconstructed image |
US10019819B2 (en) | 2012-08-30 | 2018-07-10 | Truevision Systems, Inc. | Imaging system and methods displaying a fused multidimensional reconstructed image |
US20150221105A1 (en) * | 2012-08-30 | 2015-08-06 | Truevision Systems, Inc. | Imaging system and methods displaying a fused multidimensional reconstructed image |
US11058513B2 (en) | 2017-04-24 | 2021-07-13 | Alcon, Inc. | Stereoscopic visualization camera and platform |
US10299880B2 (en) | 2017-04-24 | 2019-05-28 | Truevision Systems, Inc. | Stereoscopic visualization camera and platform |
US11083537B2 (en) | 2017-04-24 | 2021-08-10 | Alcon Inc. | Stereoscopic camera with fluorescence visualization |
US10917543B2 (en) | 2017-04-24 | 2021-02-09 | Alcon Inc. | Stereoscopic visualization camera and integrated robotics platform |
US11527323B2 (en) | 2019-05-14 | 2022-12-13 | Tempus Labs, Inc. | Systems and methods for multi-label cancer classification |
US11735302B2 (en) | 2021-06-10 | 2023-08-22 | Alife Health Inc. | Machine learning for optimizing ovarian stimulation |
Also Published As
Publication number | Publication date |
---|---|
US20120215514A1 (en) | 2012-08-23 |
EP1671121A2 (en) | 2006-06-21 |
KR20060120063A (ko) | 2006-11-24 |
US8977506B2 (en) | 2015-03-10 |
JP2012065674A (ja) | 2012-04-05 |
EP2469439A2 (en) | 2012-06-27 |
WO2005042760A2 (en) | 2005-05-12 |
EP1671121A4 (en) | 2007-12-19 |
CA2540167A1 (en) | 2005-05-12 |
JP2007507770A (ja) | 2007-03-29 |
AU2004285103A1 (en) | 2005-05-12 |
WO2005042760A3 (en) | 2005-09-09 |
IL174599A0 (en) | 2006-08-20 |
US20150161327A1 (en) | 2015-06-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8977506B2 (en) | Systems and methods for detecting biological features | |
US8321137B2 (en) | Knowledge-based storage of diagnostic models | |
Shen et al. | Prognostic meta-signature of breast cancer developed by two-stage mixture modeling of microarray data | |
US10181009B2 (en) | Methods and systems for predicting cancer outcome | |
US20230114581A1 (en) | Systems and methods for predicting homologous recombination deficiency status of a specimen | |
US20130332083A1 (en) | Gene Marker Sets And Methods For Classification Of Cancer Patients | |
US8392127B2 (en) | Methods and gene expression signature for assessing growth factor signaling pathway regulation status | |
US8600718B1 (en) | Computer systems and methods for identifying conserved cellular constituent clusters across datasets | |
JP2008536094A (ja) | 乳癌患者における化学療法反応性を予測する方法 | |
EP2419540B1 (en) | Methods and gene expression signature for assessing ras pathway activity | |
JP2008520251A (ja) | 固形腫瘍の予後および処置のための方法およびシステム | |
EP2406729B1 (en) | A method, system and computer program product for the systematic evaluation of the prognostic properties of gene pairs for medical conditions. | |
US20050069863A1 (en) | Systems and methods for analyzing gene expression data for clinical diagnostics | |
Lee et al. | A novel immune prognostic index for stratification of high-risk patients with early breast cancer | |
EP3063689A1 (en) | Methods of incorporation of transcript chromosomal locus information for identification of biomarkers of disease recurrence risk | |
Gormley et al. | Prediction potential of candidate biomarker sets identified and validated on gene expression data from multiple datasets | |
Buness et al. | Classification across gene expression microarray studies | |
CN1886658A (zh) | 用于检测生物学特征的系统和方法 | |
El-Charif et al. | Machine learning applications in cancer genomics | |
Kaindl et al. | Molecular Tools, Expression Profiling |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: PATHWORK INFORMATICS, INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ANDERSON, GLENDA G.;REEL/FRAME:016147/0607 Effective date: 20040929 |
|
AS | Assignment |
Owner name: PATHWORK DIAGNOSTICS, INC., CALIFORNIA Free format text: CERTIFICATE OF OWNERSHIP AND MERGER AND CERTIFICATE OF AMENDMENT OF PREDICANT BIOSCIENCES INC;ASSIGNOR:PATHWORK INFORMATICS, INC.;REEL/FRAME:018843/0239 Effective date: 20060630 Owner name: PATHWORK DIAGNOSTICS, INC., CALIFORNIA Free format text: CERTIFICATE OF OWNERSHIP AND MERGER AND CERTIFICATE OF AMENDMENT OF PREDICANT BIOSCIENCES INC.;ASSIGNOR:PATHWORK INFORMATICS, INC.;REEL/FRAME:018843/0239 Effective date: 20060630 |
|
AS | Assignment |
Owner name: OXFORD FINANCE LLC, VIRGINIA Free format text: SECURITY AGREEMENT;ASSIGNOR:PATHWORK DIAGNOSTICS, INC.;REEL/FRAME:029449/0797 Effective date: 20121208 |
|
AS | Assignment |
Owner name: RESPONSE GENETICS, INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:PATHWORK DIAGNOSTICS, INC.;REEL/FRAME:031615/0088 Effective date: 20130822 |
|
AS | Assignment |
Owner name: SWK FUNDING LLC, AS AGENT, TEXAS Free format text: SECURITY INTEREST;ASSIGNOR:RESPONSE GENETICS, INC.;REEL/FRAME:034848/0647 Effective date: 20140730 |
|
AS | Assignment |
Owner name: CANCER GENETICS, INC., NEW JERSEY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:RESPONSE GENETICS, INC.;REEL/FRAME:042257/0576 Effective date: 20151009 |
|
AS | Assignment |
Owner name: SILICON VALLEY BANK, MASSACHUSETTS Free format text: FIRST AMENDMENT TO INTELLECTUAL PROPERTY SECURITY AGREEMENT;ASSIGNOR:CANCER GENETICS, INC.;REEL/FRAME:042928/0668 Effective date: 20170616 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: CANCER GENETICS, INC., NEW JERSEY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:RESPONSE GENETICS, INC.;REEL/FRAME:045589/0842 Effective date: 20151009 |